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dolescents who abuse drugs possess special characteristics that include behav-
ioral problems, skills deficits, academic difficulties, family problems, and
mental health problems that generally have been shaped by environmental adver-
sities and biological vulnerabilities that began in early childhood. Developmental
studies have yielded an inventory of the risks, difficulties, and typical problems
that most often mark the developmental path of adolescents who develop sub-
stance use disorder (SUD) (Tarter, 2002; Tims et al., 2002).
Developmental research has also informed the creation of behavioral and
family-based interventions that integrate the treatment of adolescent drug abuse
with efforts to address other problems associated with adolescent SUD; these inter-
ventions have been captured in manuals to guide treatment providers (Drug
Strategies, 2002). A growing research and clinical consensus indicates that treat-
ment for adolescents is most effective when it attends to the patients’ many psy-
chosocial problems and mental health needs in addition to their drug abuse. There
is also evidence that an increasing number of community-based treatment pro-
grams are successfully implementing integrated treatment services (Drug Strategies,
2002; National Institute on Drug Abuse, 1999).
Despite these advances, integrated treatment of comorbid psychiatric dis-
orders in drug treatment programs for adolescents has trailed other integrated
treatment services because of clinical and systemic barriers. These include a 
critical shortage of child/adolescent psychiatrists with training in addictions, poor 
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third-party payer coverage for integrated psychiatric
services, and the longstanding separation of provider
networks for psychiatric and substance abuse treat-
ment (Rotheram-Borus and Duan, 2003). 
Another barrier has been the lack of research on
adolescents to support the development of integrated
“best practice” standards (Weinberg et al., 1998).
Fortunately, recent studies have begun to address this
significant research gap. A primary focus of this arti-
cle is an overview of recent scientific advances, high-
lighting how research can guide the development of
practice standards to improve treatment outcomes for
dually diagnosed adolescents.
PATHS TO ADOLESCENT SUD
Adolescents who enter substance abuse treatment pro-
grams are more likely than peers who do not abuse
drugs to have had a “difficult temperament” as tod-
dlers or preschoolers, characterized by oppositional
behavior, aggressiveness, impulsivity, and poor frus-
tration tolerance (Tarter, 2002). They are also more
likely to have experienced abuse or neglect and sig-
nificant family problems and to have developed a psy-
chiatric disorder during early childhood, such as a
learning disability (LD), attention-deficit/hyperac-
tivity disorder (ADHD), or oppositional defiant
disorder (ODD). Behavioral, psychosocial, and men-
tal health problems often have hindered their adjust-
ment to school and led to placement in separate classes
for the behaviorally and learning disabled, increasing
their association with peers with similar vulnerabili-
ties, including elevated risk for school failure and for
developing conduct disorder (CD) (Tarter, 2002).
In youths with such histories, limited experiences
of academic success or mastery often lead to demor-
alization by the end of elementary school and to mid-
dle school careers marked by escalating behavior prob-
lems, increased social marginalization and association
with deviant peers, and early onset of substance abuse.
Early substance abuse, coupled with the neurohor-
monal changes of puberty, impacts the development
of the brain and neuroendocrine system in ways likely
to contribute to the onset or exacerbation of preex-
isting psychiatric disorders, such as CD, ADHD, and
mood or anxiety disorders (Crowley and Riggs, 1995;
Rutter et al., 1998).
By the time an adolescent enters substance treat-
ment, he or she often has reaped the cumulative psy-
chological, health, and social consequences of earlier
developmental adversities and behavior problems
(Rutter et al., 1998; Tims et al., 2002). Newly pre-
senting adolescent patients are often poorly motivated
for treatment and have psychiatric problems; wors-
ening academic, family, and behavior problems; and
a limited range of coping and social skills. They are
also likely to lag in important adolescent develop-
mental tasks, including individuation, moral devel-
opment, and conceptualization of future educational,
vocational, and family goals (Rutter et al., 1998; Tims
et al., 2002). The complexity of the problems these
youths typically bring to drug abuse treatment under-
scores their need for multimodal approaches that
address a broad range of mental health and psychosocial
problems as well as drug abuse. The following section
overviews research-based treatment modalities for ado-
lescent SUD and research on treatments for the comor-
bid disorders most commonly seen in these youths.
RESEARCH-BASED INTERVENTIONS FOR
ADOLESCENT SUD 
Pharmacotherapy  
Many medications commonly used to treat adult SUD
have not been evalulated in controlled trials with ado-
lescents. Such medications include substitution/replace-
ment therapies (e.g., methadone and buprenorphine),
opioid antagonists (e.g., naltrexone), aversive thera-
pies (e.g., disulfiram), or anticraving medications (e.g.,
bupropion and naltrexone) (Solhkhah and Wilens,
1998). If these medications are used in treating ado-
lescents, they must be used with caution, careful mon-
itoring, and consideration of the developmental char-
acteristics that distinguish adolescents from adults,
such as greater impulsivity and polydrug use (Deas et
al., 2000). 
Behavioral or Psychosocial Interventions
Research on behavioral/psychosocial interventions for
adolescent SUD has made significant advances in the
past decade. Controlled trials now provide good evi-
dence that several psychosocial treatment approaches
can be effective in treating adolescent SUD and other
associated problems. Some of these interventions
are based on modalities that have been effectively used
with adults and modified substantially to make them
developmentally appropriate for adolescents (Deas et
al., 2000; Drug Strategies, 2002; Wagner et al., 1999).
Among the modalities with substantial research 
support: 
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Family-based interventions include structural-
strategic family therapy, parent management training
(PMT), multisystemic therapy (MST), and multidi-
mensional family therapy (MDFT). They are based
on family systems theory and share the assumption
that dysfunctional family dynamics contribute to ado-
lescent SUD and related problems. In practice, clini-
cians perform a functional analysis to identify prob-
lem behaviors, and relationship patterns that are then
targeted with restructuring interventions. Parents are
taught better monitoring skills and basic behavioral
management principles to improve their adolescent’s
behavior and reduce drug abuse together with strate-
gies to improve overall family functioning and sustain
the gains of treatment (Drug Strategies, 2002; Wagner
et al., 1999).
Behavioral therapy approaches are based on
operant behavioral principles that include reward-
ing behaviors or activities that are incompatible
with drug use and withholding rewards or applying
sanctions when drug use or other targeted behaviors
occur. This provides a constructive reinforcement sys-
tem to help promote desired behaviors and extinguish
those related to drug use. Urine monitoring to detect
drug use is indispensable to linking consequences as
closely as possible to the targeted behaviors. Studies
of adolescents indicate that it is important both to
provide individual behavioral therapy and to involve
the family in treatment. Behavioral therapy has been
shown to help adolescents become drug free and to
improve problems in other areas, such as employment,
school attendance, family relationships, conduct prob-
lems, and depression (Azrin et al., 1994; National
Institute on Drug Abuse, 1999).
Cognitive-behavioral therapy (CBT), based on
learning theory, also has been shown to be effective in
treating adolescent SUD (Drug Strategies, 2002;
Wagner et al., 1999). Although there is more empir-
ical support for individual CBT, preliminary studies
indicate that group CBT may also reduce adolescent
substance use and improve other problem behaviors
(Kaminer et al., 1998). Treatment manuals have been
developed for courses of weekly CBT treatment rang-
ing from 5 to 16 weeks. Features common to most
CBT models include:
• Employing motivation-enhancing techniques to
establish a strong treatment alliance and improve
treatment engagement and retention; 
• Performing a functional analysis to identify patterns
of substance use, skills deficits, and dysfunctional
attitudes and thinking that then become specific tar-
gets of intervention;
• Enhancing coping strategies to effectively deal with
drug craving, negative moods, and anger;
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• Strengthening problemsolving and communication
skills and the ability to anticipate and avoid high-
risk situations; and
• Identifying enjoyable activities incompatible with
drug use.
New skills and coping strategies are initially taught
and practiced during therapy sessions, then applied
to the patient’s daily life in “homework” assignments,
with a review of successes and setbacks the follow-
ing week (Drug Strategies, 2002; Wagner et al., 1999).
Motivational enhancement therapy (MET) has
been used both as a standalone, brief intervention (for
example, among adolescents presenting to emergency
rooms with alcohol-or drug-related injuries) and inte-
grated with other modalities such as CBT (Monti et
al., 2001). It is a client-centered approach that helps
patients resolve ambivalence about engaging in treat-
ment and strengthen their motivation to build a plan
for change. MET has been shown to improve treat-
ment commitment and motivation and reduce sub-
stance abuse and risky behaviors (for instance, drunk
driving and unsafe sex). Utilizing MET techniques is
particularly important for adolescents, as they are gen-
erally resistant to more directive approaches and are
often ambivalent about committing to abstinence
(Drug Strategies, 2002; National Institute on Drug
Abuse, 1999). 
Community reinforcement therapy combines
principles and techniques derived from behavioral,
cognitive-behavioral, motivational, and family ther-
apy, often using incentives to enhance treatment out-
comes (Drug Strategies, 2002). 
Research is needed to identify which compo-
nents of the research-based modalities are integral and
must be implemented with close adherence to the
treatment manual to be effective and which compo-
nents—if any—may be eliminated or modified for
adaptation to local settings. This is a significant gap
in our knowledge and has important implications for
dissemination of evidence-based practice, given the
increasing number of community-based treatment
programs that are incorporating or combining all or
portions of these modalities into their standard treat-
ment.
Although each of these research-developed modal-
ities is underpinned by a somewhat different theo-
retical model, all share several common features. All
employ empathic, supportive, motivationally enhanc-
ing techniques, behavioral and cognitive-behavioral
approaches. All emphasize the importance of per-
forming a comprehensive evaluation or functional
analysis to identify a broad range of problems asso-
ciated with drug abuse, which then become targets of
intervention. All stress the importance of including
the family in treatment in addition to providing indi-
vidual and/or group counseling.  
There is also evidence that using a combina-
tion of treatment modalities to target a broader range
of problems may be an effective strategy. A recent study
systematically evaluated community-based adolescent
substance treatment programs nationwide. An expert
panel of clinicians and researchers asked knowledge-
able community and organizational sources nation-
wide to identify programs they considered the best in
their area, or which they would recommend to a fam-
ily member or close friend (Drug Strategies, 2002).
An examination of the treatment offerings of a subset
of these 144 “exemplary” programs reveals striking
overlap with the commonly shared components of the
research-developed modalities. The shared compo-
nents include:
• Comprehensive, systematic evaluation to identify
problems and treatment needs in multiple domains,
including psychiatric comorbidity;
• Use of empathic, supportive, and motivation-
enhancing techniques to improve alliance, engage-
ment, and retention;
• Use of behavioral techniques informed by urine tox-
icology results to promote and shape desired, pro-
social behaviors and discontinuation of drug use and
other problem behaviors; 
• Use of cognitive-behavioral and skills-building tech-
niques delivered in an individual or group format
to enhance adolescents’ self-efficacy, problemsolv-
ing, decisionmaking, communication, anger man-
agement, mood regulation, coping, and relapse pre-
vention skills. These techniques are often used to
help adolescents anticipate and avoid high-risk
situations and identify triggers for drug use, decrease
association with drug-using peers, and encourage
involvement in enjoyable, prosocial activities incom-
patible with drug use;
• Involvement of the family in an adolescent’s treat-
ment, emphasizing enhancement of parental mon-
itoring and behavioral management skills and use
of restructuring interventions to correct dysfunc-
tional patterns of interaction, relationships, and
behaviors to improve overall family functioning;
Motivational
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• Emphasis on relapse prevention and the need for
continuing care, including development of specific
plans to manage relapse;
• Focus on adequate training and ongoing staff devel-
opment activities for counselors and program spe-
cialists;
• Emphasis on providing developmentally appropri-
ate interventions, often including specialized 
program components such as gender-specific or 
culture-specific programming; 
• Focus on evaluating treatment outcomes; and
• Emphasis on the importance of integrating the assess-
ment and treatment of comorbid psychiatric disor-
ders with substance abuse treatment.
In summary, both research and community treat-
ment programs are converging on a consensus that
treatment for adolescents is most effective when mul-
timodal treatment services are provided and integrated.
Although it would be premature from a scientific stand-
point to say that the components common to both
research-developed and “model” community-based
programs are the essential or active ingredients of effec-
tive treatment, they can certainly be considered
clinically important components of adolescent 
treatment.
TREATMENT FOR COMORBID DISORDERS 
Current research supports integrating the treatment
of co-occurring psychiatric disorders with treatment
for drug abuse by adolescents (Drug Strategies, 2002;
National Institute on Drug Abuse, 1999). The find-
ings can be summarized as follows: 
• Adolescents with SUD and comorbid psychiatric
disorders have poorer drug treatment outcomes than
those with only SUD. The probable reason is that
psychiatric illness frequently goes untreated among
dually diagnosed adolescents and reduces the like-
lihood of successful engagement, retention, and
completion of substance abuse treatment (Grella et
al., 2001; Lohman et al., 2002; Wise et al., 2001). 
• Untreated comorbid psychiatric disorders such as
ADHD or mood disorders persist even after suc-
cessful substance abuse treatment produces absti-
nence. Depression is much less likely to remit
with abstinence in adolescents than in depressed
adults with chronic alcohol or drug dependence
(Bukstein et al., 1992; Riggs et al., 1996). 
• Recent controlled trials indicate that treatment of
comorbid psychiatric disorders alone is not likely to
significantly reduce substance use or induce absti-
nence in dually diagnosed adolescents (Geller et al.,
1998; Lohman et al., 2002; Riggs et al., 2001).
Until very recently, almost nothing was known
about the safety and efficacy of medications for treat-
ment of psychiatric disorders in adolescents with SUD
or the potential for adverse interactions with drugs of
abuse. Thus, clinicians have been understandably
reluctant to treat psychiatric disorders with medica-
tions in this population, often referring youths for
substance abuse treatment before considering treat-
ment of psychiatric comorbidity. This sequential
approach is cautious, but it perpetuates a clinical
conundrum. Treatment for the comorbid disorder is
withheld pending successful drug abuse treatment and
achievement of abstinence, but the untreated psychi-
atric illness significantly diminishes the likelihood of
successful drug abuse treatment.
While caution is reasonable and abstinence ideal
before initiation of pharmacotherapy for a comorbid
disorder, treatment risks must be balanced against the
potential consequences of leaving psychiatric illness
untreated. For example, many adolescents in substance
treatment programs have been court-mandated to
treatment. If their psychiatric disorders are not treated
soon after admission for substance treatment, their
chances of failing treatment may be increased and may
result in incarceration with few or no treatment options
(Grella et al., 2001; Teplin et al., 2002; Wise et al.,
2001).
Recent controlled clinical trials have begun to
extricate clinicians from the conundrum of sequen-
tial treatment by demonstrating the safety and effi-
cacy of medications for some of the most common
psychiatric comorbidities, namely bipolar disorder,
depression, and ADHD. Although there is not yet
consensus on “best practices” for the use of medica-
tions to treat comorbid disorders for adolescents’ dual
diagnosis, these recent advances offer preliminary evi-
dence for an integrated treatment strategy, moving
current practice standards forward until research can
guide further refinement.
Pharmacotherapeutic Options 
For Comorbid Disorders
While we have substantial knowledge about pharma-
cotherapy for common comorbid disorders of ado-
lescents with SUD, it is important to note that med-
ications are not the first-line treatment approach for
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all comorbid disorders. For example, behavioral inter-
ventions and family-based therapies are considered
the first-line treatment for conduct disorder, the most
common comorbidity associated with SUD in ado-
lescents (see review by Riggs and Whitmore, 1999).
Many drug treatment programs already provide these
or similar behavioral interventions, since these modal-
ities treat both CD and SUD, especially if augmented
with voucher incentives or contingency management
techniques more specific to substance abuse treatment
(Drug Strategies, 2002).   
ADHD
Pharmacotherapy with psychostimulants is consid-
ered first-line treatment for ADHD in children and
adolescents without SUD. Only one controlled med-
ication trial has been conducted in adolescents with
ADHD and SUD. In this study, 69 out-of-treatment
adolescents with CD, SUD, and ADHD were recruited
from the community and randomized to receive either
placebo or pemoline (a psychostimulant with low
abuse potential compared to the relatively high abuse
liability of schedule II psychostimulants such as
methylphenidate). Results showed that pemoline’s
safety and efficacy in treating ADHD in nonabstinent
adolescents was similar to that reported for adoles-
cents without SUD (Riggs et al., 2001). Despite its
efficacy for ADHD, pemoline did not reduce sub-
stance use in the absence of specific treatment for
SUD. Although no patients in this trial developed
serious side effects or elevations in liver enzymes, recent
concerns about the rare but serious potential for liver
toxicity with pemoline have led to recommendations
for frequent monitoring of liver enzymes (Safer et al.,
2001). This restriction has diminished the clinical fea-
sibility of using pemoline, especially in outpatient set-
tings. Nonetheless, pemoline is still considered an
important treatment option for ADHD in settings
requiring the use of medications with low abuse poten-
tial and once-per-day dosing regimens.
Fortunately, newer medications with low abuse
liability, such as bupropion and atomoxetine, have
been shown to be effective for ADHD in adults and
adolescents without SUD (Michelson et al., 2002;
Wilens et al., 2001). Bupropion may also be helpful
in treating both ADHD and depression in adolescents
and adults without SUD (Daviss et al., 2001). Bupropion
has also been reported to have a good safety profile
without serious adverse effects in cannabis-depend-
ent adults who were smoking marijuana up to five
times per day (Haney et al., 2001). Given these data,
clinicians may wish to consider bupropion as a treat-
ment option for adolescents with SUD, ADHD, and
depression, again with the caveat that no controlled
trials have yet been completed in adolescents with
SUD. 
Bipolar Disorder
Pharmacotherapy with mood stabilizers (e.g., lithium,
valproic acid, carbamazepine) is the first-line treat-
ment for bipolar disorder in adolescents without SUD.
Only one controlled trial (lithium versus placebo) has
been conducted in adolescents with bipolar disorder
and SUD (Geller et al., 1998). In this study, lithium
had a relatively good safety profile and was shown to
be effective in stabilizing mania or hypomania, despite
ongoing substance use by most subjects during the
trial. As mood began to stabilize in the lithium-treated
patients, substance use declined somewhat more than
in those treated with placebo. However, pharma-
cotherapy for bipolar disorder was not effective in
treating SUD or inducing abstinence in the absence
of specific substance treatment. These data support
treating bipolar disorder in the context of concurrent
treatment for SUD. No data are yet available from
controlled trials about the safety or efficacy of other
mood stabilizers in this population.
Depression
Current practice guidelines recommend that adoles-
cents with severe depression receive both psychother-
apy and pharmacotherapy, while those with mild or
moderate symptoms may be offered a trial of psy-
chotherapy alone before medications are considered
(Birmaher et al., 1998). Both CBT and interpersonal
psychotherapy have demonstrated efficacy for depres-
sion in adolescents without SUD (Birmaher et al., 1998).
Selective serotonin reuptake inhibitors (SSRIs)
are considered first-line medications for treatment of
adolescent depression without comorbid SUD, with
most evidence for fluoxetine (Emslie et al., 2002). No
adequately powered controlled trials of SSRIs have yet
been completed in adolescents with SUD. However,
preliminary data from an ongoing randomized con-
trolled trial of fluoxetine for depression in 120 ado-
lescents with CD and SUD indicate that the medica-
tion appears to have a very good safety profile even in
nonabstinent adolescents with polydrug abuse (Lohman
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et al., 2002). Although efficacy data are not yet avail-
able from this ongoing trial, data from open trials and
one small controlled trial indicate some promise for
the safety and efficacy of SSRIs for depression in ado-
lescents with SUD (Deas and Thomas, 2001; Riggs,
1997). Clinically, SSRIs are frequently used by both
adult and adolescent addiction psychiatrists as first-
line medications for the treatment of comorbid depres-
sion with SUD (Deas and Thomas, 2001). If ADHD
is also present, bupropion may be considered, given
its efficacy for both disorders and preliminary data
indicating a favorable safety profile in cannabis-depend-
ent adults and in an open-label trial in adolescents
with SUD (Haney et al., 2001; Riggs et al., 1998;
Riggs and Davis, 2002; Wilens et al., 1997).
Tricyclic antidepressants are contraindicated for
the treatment of depression or ADHD in adolescents
with SUD. These agents have significant anticholiner-
gic and cardiac side effects, a relatively high potential
for adverse interactions with substances of abuse (espe-
cially cannabis), and considerable danger of causing
death if an overdose should occur (Wilens et al., 1997).
Anxiety Disorders
Cognitive-behavioral therapies, often combined with
SSRI medications, are considered best practice for a
spectrum of anxiety disorders in adolescents with-
out SUD (March and Wells, 2002). Although no con-
clusive randomized trials have yet been completed
in adolescents with SUD, preliminary results suggest
that CBT may also be helpful in treating anxiety
disorders, including posttraumatic stress disorder
(PTSD), in this population (Najavits, 2003). While
SSRI treatment for anxiety disorders in substance-
abusing adolescents has not been well studied, clini-
cians may wish to consider SSRIs for treatment of anx-
iety disorders in dually diagnosed adolescents in
conjunction with SUD treatment, given the available
data (from previously mentioned depression stud-
ies) indicating that fluoxetine (an SSRI) appears to
have a favorable safety profile even in nonabstinent
adolescents (Lohman et al., 2002). Such medications
may be particularly useful in managing the sleep prob-
lems, depressive symptoms, intrusive memories, and
hyperarousal symptoms often associated with PTSD
(March and Wells, 2002). Benzodiazepines are con-
traindicated for anxiety disorders in patients with SUD
because of their well-known abuse potential.
IMPLEMENTING INTEGRATED TREATMENT
Screening
Given the high prevalence of comorbid psychiatric
disorders and their adverse impact on substance treat-
ment engagement and retention, treatment programs
should try to develop the capability of early screening
for comorbid disorders. Several screening instruments
have been developed for this purpose in addition to
longer structured diagnostic instruments. Treatment
programs should use standard assessment instruments
that have been rigorously evaluated for reliability and
validity. Reviews can be found in several sources
(Crowley et al., 2001; Drug Strategies, 2002; National
Institute on Drug Abuse, 1999; Winters et al., 1996).
Counselors or team specialists can learn to
clinically screen for symptoms of psychiatric disor-
ders, referring affected patients for psychiatric eval-
uation. Programs can provide staff with the appro-
priate training in a number of ways, including psychiatric
inservice training that includes information on the
symptoms of common comorbid disorders and the
most commonly used medications and their side effects.
Once trained, counselors can play an important role
throughout treatment in monitoring target symptom
response, psychosocial functioning, and treatment
progress, including urine toxicology results and iden-
tification of adverse side effects. They also can relay
this information to the staff or consulting psychiatrist
or a program mental health specialist. Designating
one clinician (or team specialist) to be the single point
liaison who communicates regularly with the treating
psychiatrist regarding new consultations and ongoing
medication followup promotes efficiency of commu-
nication and good clinical monitoring practices. 
The Clinical Interview and Evaluation
In general, an adolescent’s parents or caretakers should
be present at his or her initial clinical interview. Their
presence enables the counselor to establish the rules
of confidentiality (including that reports of abuse,
neglect, or threats of harm to self or others must be
disclosed), obtain early development history, and assess
family dynamics. Subsequently, a private interview
with the adolescent is important to facilitate a strong
treatment alliance and elicit candid information about
substance abuse and behavior problems that the patient
may not be comfortable disclosing with parents pres-
ent. It is crucial that clinicians use an empathic, non-
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judgmental, supportive, and motivation-enhancing
interview style with adolescent patients.
Adolescents’ self-reports of drug use have been
shown to be reliable in the assessment context when
confidentiality is assured (Winters et al., 1990). The
patient’s self-reports of his or her dynamics of sub-
stance use and problems related to drug use provide
the foundation for collaborative goal setting and effec-
tive treatment planning. For each substance of abuse,
clinicians should assess DSM-IV diagnostic criteria
for substance abuse and dependence. They should
then ask the adolescent about the onset of use for each
substance; progression, patterns, and frequency of
use; use in combination with other substances;
presence of tolerance or withdrawal symptoms; and
response to any previous treatment. Other important
information includes triggers for craving and use (such
as parents fighting, coping with low moods, and stress);
context of use (for example, peer influence and use at
school); perceived motivation for using; positive and
negative consequences of use; and current motivation
and goals for treatment (Drug Strategies, 2002; Riggs
and Davies, 2002).
Clinicians may find it useful to map relevant
developmental history and the onset and progression
of both psychiatric symptoms and substance abuse
onto a lifetime timeline. Organizing the assessment
information along a timeline enables clinicians to
evaluate the impact of developmental adversities (for
example, abuse and neglect, parental divorce, and sig-
nificant losses) on current problems and elucidate the
temporal relationship between psychiatric symptoms
and substance use—especially periods of intoxica-
tion, withdrawal, and abstinence. This facilitates
meaningful clinical formulations and diagnostic
impressions to better guide treatment planning (Riggs
and Davies, 2002).
Treatment Design and Delivery
The following step-by-step approach to treatment can
be modified as appropriate to the details of each case
and with consideration of available family, clinical,
psychiatric, and program resources, such as clinical
staff and training and community resources.
Step 1. Convene the entire treatment team in
a comprehensive case conference. Include substance
abuse counselors, line staff, education specialists, the
consulting psychiatrist or program mental health spe-
cialist, family therapist, and representatives from
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involved outside agencies (such as a social worker,
case manager, and probation officer). Together, sys-
tematically review and integrate the assessment infor-
mation from all sources and perspectives, including
the patient’s statement of treatment goals, in order to
develop a problem list for targeted interventions.
Treatment goals and intervention effectiveness should
be regularly reviewed and modified, if necessary, as
the patient progresses in treatment.
Step 2.The initial focus of treatment should be
to engage the adolescent by establishing a strong 
treatment alliance and collaboratively developed 
goals to stabilize substance abuse and begin to address
comorbid disorders as well as other problems. 
Ideally, motivation-enhancing techniques should be
used with other empirically supported individual
and/or group therapies (such as CBT), as well as fam-
ily-based treatment modalities previously reviewed
(Deas and Thomas, 2001; Wagner et al., 1999).
Adolescents may also benefit from participation in
a 12-step program as a component of multidimen-
sional, multimodal treatment (Deas and Thomas,
2001). In addition to individual counseling and group
therapy treatment components, the family should be
included in the adolescent’s treatment.
Step 3. If the adolescent has a comorbid disor-
der for which medication is being considered (for
example, ADHD or major depression), the following
procedure may help guide medication initiation and
monitoring. Abstinence is ideal before medication is
started, but clinicians must weigh the risk of poten-
tial drug-medication interactions against the risk that
the untreated psychiatric illness will thwart treatment
engagement, precipitate early dropout, or interfere
with achievement of abstinence. It may be neces-
sary to tolerate some ongoing alcohol or cannabis use
during the initial phase of treatment. Once the ado-
lescent is engaged in substance abuse treatment and
both urine drug screening and self-report indicate
either abstinence or reduction in substance use, work
with the mental health professional or psychiatrist to
develop a plan for regular monitoring and informa-
tion exchange on compliance with substance abuse
treatment, urine toxicology results, target symptom
response, and emergence of adverse side effects.
When initiating medications, the patient should
comply with at least weekly therapy sessions. Preliminary
evidence and clinical experience indicate that using
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empathic, encouraging therapeutic approach may
induce consistent attendance and reduced substance
use after 2 to 4 weeks of treatment, such that med-
ication for comorbidity often can begin during the
first month of treatment. Moreover, in our clinical
research protocols, medication for depression or
ADHD is started in the first week after study admis-
sion for adolescents who generally are active users
of substances of abuse (Lohman et al., 2002; Riggs et
al., 2001).  
The following principles may be helpful in guid-
ing medication management for comorbid adoles-
cents: 
• When medication is indicated, consider medica-
tions with good safety profiles, low abuse liability,
and once-per-day dosing, if possible;
• Use a single medication if at all possible;
• Provide the patient and family with information
about the potential for adverse interactions of med-
ications with substances of abuse and the need for
abstinence or reduced substance use to ensure safety
and efficacy;
• Establish mechanisms to closely monitor medica-
tion compliance (initially weekly), adverse effects,
target symptom response, and ongoing substance
use (using both self-report and urine drug screen-
ing);
• Monitor compliance with regular substance abuse
treatment (generally, individual and/or family coun-
seling at least weekly) and regular urine drug screen-
ing (if not the primary substance treatment provider);
and
• Monitor patient treatment motivation and target
symptom response and behavior changes and psy-
chosocial functioning throughout treatment.
Step 4. If substance abuse or target symptoms
of the comorbid disorder do not significantly improve
within the first 2 months of treatment, or if there is
evidence of drug abuse escalation or clinical deteri-
oration, reevaluate or consider changing the medica-
tion, reassessing the diagnosis (for example, bipolar
versus unipolar depression), and increasing the level
of care or treatment frequency.
Step 5.Talk with the patient about relapse
prevention strategies and the need for continuing care
with regular followup for his or her psychiatric dis-
order and SUD. Lack of followup and treatment com-
pliance for either disorder increases risk of relapse and
destabilization of the psychiatric disorder. The poten-
tial for relapse after an acute treatment episode is high,
as is characteristic of many chronic, relapsing illnesses.
Therefore, it is critical to discuss this frankly and
develop before discharge a realistic, workable plan for
anticipating and managing relapses and a plan for
continuing care. It is also important to emphasize that
relapse is common and represents neither personal
failure nor treatment failure. 
Little research is available to guide the optimal
treatment length, frequency, and modalities that are
most effective for continuing care. Treatment pro-
grams and clinicians should work flexibly and cre-
atively with patients, families, and available commu-
nity resources to develop workable plans for continued
monitoring of drug use, managing relapses when they
occur, and mental health followup. Primary care physi-
cians (PCPs) can often be enlisted to help in this
process by regularly checking in with adolescent
patients, obtaining urine drug screens, and assess-
ing the stability of psychiatric comorbidity. It is help-
ful for the substance abuse and psychiatric treatment
providers to liaise with PCPs to provide them with
specific referral information if they become concerned
that the patient has relapsed or if the level of func-
tioning has declined.
Encouraging involvement in 12-step groups or
other self-help support efforts can also be an impor-
tant component of continuing care and relapse pre-
vention. Another is to encourage teens while still in
treatment to become involved in an enjoyable, proso-
cial activity that is incompatible with drug use (for
example, martial arts). An important area for future
research is to evaluate whether involvement in such
community-based activities complements other relapse
prevention efforts and helps sustain the gains of treat-
ment.
SUMMARY, IMPLICATIONS FOR RESEARCH
Controlled efficacy trials, coupled with the results of
systematic treatment program evaluation, clearly indi-
cate that treatment for adolescent SUD is effective in
reducing drug use and improving associated behav-
ioral, familial, and psychosocial outcomes. The evi-
dence also indicates that these outcomes are enhanced
when a combination of modalities is offered in a com-
prehensive, integrated treatment plan that addresses
drug abuse and a broad range of biopsychosocial prob-
lems, skills deficits, and psychiatric problems. Although
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Comorbid Disorder
Conduct Disorder
(CD)
Attention-Deficit/
Hyperactivity
Disorder (ADHD)
Depression
Anxiety Disorders
(often comorbid
with depression;
includes posttrau-
matic stress disor-
der [PTSD])
Bipolar
Disorder
Prevalence Among
Adolescents With 
SUD
60-80%
30-50%
15-25%
15-25%
10-15%
Effective Treatment for 
Adolescents Without SUD
• Multisystemic therapy or other 
behavioral, family-based inter-
vention
• Pharmacotherapy (generally, 
psychostimulants)
• Medication options with low 
abuse potential: pemoline, 
bupropion, atomoxetine 
• Combined pharmacotherapy and 
psychotherapy
• Pharmacotherapy: SSRIs in 
adolescents without SUD
• Psychotherapy: cognitive-
behavioral therapy (CBT) and 
interpersonal psychotherapy, 
combined with medication for 
severe depression
• Combined psychotherapy 
(CBT) and pharmacotherapy 
(SSRI)
•  Pharmacotherapy
•  Mood stabilizers (lithium, 
valproic acid, carbamazepine)
Impact of Treatment on Adolescents
With SUD
Decreases both CD and substance 
use, especially when augmented 
with specific behavioral interven-
tion for SUD
One controlled trial of pemoline
suggests:
• Effective for ADHD
• Good safety profile
• No impact on SUD without sub-
stance abuse treatment
• Research is needed on other 
low-abuse medication
Preliminary evidence suggests:
• SSRIs may reduce depression, but 
are inadequate for SUD in the 
absence of specific substance 
abuse treatment
• Good safety profile for fluoxetine 
(SSRI) in nonabstinent adoles-
cents in one randomized, 
controlled trial
• Bupropion may be effective for 
depression and ADHD in adoles-
cents; fairly good safety profile 
with comorbid SUD
•T ricyclics contraindicated
Preliminary evidence suggests:
•  CBT and SSRIs effective for 
anxiety disorders/PTSD but 
inadequate for SUD without spe-
cific SUD treatment
One randomized controlled trial of
lithium for bipolar disorder with
SUD suggests:
• Pharmacotherapy is effective 
for bipolar disorder but not 
adequate for SUD without 
specific SUD treatment
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stance abuse treatment, the place of medications in
substance abuse treatment, and the clinical implica-
tions of developmental vulnerabilities and adversities
in the lives of adolescents in our treatment programs.
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with substance abuse treatment has lagged behind
integration of other treatment services, recent advances
in the state of the science can now better inform prac-
tice guidelines.
The integrated treatment model presented here
is grounded in current research and may serve as a
helpful guide for clinicians until further research can
contribute to its refinement. Beyond the need for
more research, further progress in implementing inte-
grated treatment in community-based programs may
require fresh attitudes about sequential and integrated
treatment models, the importance of assessing and
treating comorbid disorders in conjunction with sub-
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Franklin Ingram: It’s awfully hard to convince teenagers
that they can suffer any adverse effects from using
alcohol or other drugs. Adolescents all think they are
bulletproof. They think injury and death can happen
to other kids, but not themselves.
Joe Richard: One thing I have noticed about adoles-
cents is that they are very resilient, especially their
bodies; they can bounce back from overdoses and trau-
mas. I also think they are a lot more accessible than
adults. Not all of them, but as a group they seem to
be more amenable to exploring the possibility that
they have a problem. And they have a lot more con-
nections than adults. A lot of adults have burned their
bridges and they don’t have as much support.
Patricia Chandler: One obvious thing about ado-
lescents is that we have their parents to contend with.
They are usually a huge factor in the exacerbation
of the illness. And often that is a big roadblock.
Ingram: I have noticed that a very high percentage
of the adolescents we work with, at age 14 or so, have
a parent or guardian who also has a drug problem.
Chandler: That brings up an issue: A huge number
of these kids, especially the girls, have been sexually
abused. Abuse is common, and right now there is not
much effective help available for these individuals.
Ingram: For some kids we ought to come up with
something other than family treatment, because the
family is what has wounded them so badly.
Treating comorbid disorders
Ingram: What is most important to me about this
subject and this article is the increased efficacy we
would get if we actually treated patients’ comorbid
conditions along with their substance abuse disor-
ders. That is locally lacking in most adolescent sub-
stance abuse outpatient programs I know about.
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